Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC25A1 | P53007 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.64 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.64 |
| ▸ | CASP6 | P55212 | 4/20 | 0.62 |
| ▸ | SLC10A2 | Q12908 | 1/20 | 0.61 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.61 |
| ▸ | SLC10A6 | Q3KNW5 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.56 |
| ▸ | ACLY | P53396 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | KDM4A | O75164 | 1/20 | 0.56 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30000258 | 1.00 | SLC25A1 (1.00) | SLC25A1MEN1KMT2ALMNADNMT1 | |
| SCHEMBL5598171 | 1.00 | SLC25A1 (1.00) | SLC25A1MEN1KMT2ALMNADNMT1 | |
| SCHEMBL30777865 | 1.00 | SLC25A1 (1.00) | SLC25A1MEN1KMT2ALMNADNMT1 | |
| SCHEMBL10389335 | 0.86 | SLC25A1 (0.75) | SLC25A1MEN1KMT2ALMNADNMT1 | |
| SCHEMBL34475240 | 0.84 | MEN1 (0.78) | SLC25A1MEN1KMT2ALMNAPOLB | |
| SCHEMBL27770307 | 0.84 | MEN1 (0.78) | SLC25A1MEN1KMT2ALMNAPOLB | |
| SCHEMBL31404880 | 0.84 | SLC25A1 (0.72) | SLC25A1MEN1KMT2ALMNADNMT1 | |
| SCHEMBL13146602 | 0.82 | SLC25A1 (0.69) | SLC25A1KMT2ALMNADNMT1DNMT3A | |
| SCHEMBL11749307 | 0.81 | SLC25A1 (0.68) | SLC25A1MEN1KMT2ALMNADNMT1 | |
| SCHEMBL10695037 | 0.81 | MEN1 (0.73) | SLC25A1MEN1KMT2ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119055773-A | Drug for reversing drug resistance of EGFR-TKI of third generation lung cancer | 华中农业大学 | 2024-12-03 | — | — | CN | claimed |
| US-20220323389-A1 | TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND INFLAMMATORY STEATOHEPATITIS WITH SLC25A1 INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2022-10-13 | — | — | US | claimed |
| CN-120757475-A | Small molecule inhibitor CTP13 targeting SLC25A1 and application thereof | 中国医科大学附属第一医院 | 2025-10-10 | — | — | CN | disclosed |
| CN-119055773-B | Application of CTPI-2/Orlistat/Etomoxir in preparation of medicine for reversing EGFR-TKI octenib resistance of third generation lung cancer | 华中农业大学 | 2025-06-06 | — | — | CN | disclosed |
| CN-119055773-B | Application of CTPI-2/Orlistat/Etomoxir in preparation of medicine for reversing EGFR-TKI octenib resistance of third generation lung cancer | 华中农业大学 | 2025-06-06 | — | — | CN | disclosed |
| CN-119205162-A | Shaanxi coal price index calculation method | 陕西煤炭交易中心有限公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119055773-A | Drug for reversing drug resistance of EGFR-TKI of third generation lung cancer | 华中农业大学 | 2024-12-03 | — | — | CN | disclosed |
| CN-119055773-A | Drug for reversing drug resistance of EGFR-TKI of third generation lung cancer | 华中农业大学 | 2024-12-03 | — | — | CN | disclosed |
| CN-116019811-B | Application of GSK-J4 in preparation of medicine for resisting gram positive bacteria infection | 华中科技大学协和深圳医院 | 2024-04-12 | — | — | CN | disclosed |
| WO-2023237873-A1 | TARGETS FOR CANCER THERAPY | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2023-12-14 | — | — | WO | disclosed |
| EP-4181911-A1 | THE ROLE OF PMCIC IN THE TUMOR MICROENVIRONMENT | Universitätsklinikum Regensburg (DE) | 2023-05-24 | — | — | EP | disclosed |
| CN-116019811-A | Application of GSK-J4 in preparation of medicine for resisting gram positive bacteria infection | 华中科技大学协和深圳医院 | 2023-04-28 | — | — | CN | disclosed |
| US-20220323389-A1 | TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND INFLAMMATORY STEATOHEPATITIS WITH SLC25A1 INHIBITORS | GEORGETOWN UNIVERSITY (US) | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220323389-A1 | TREATING NON-ALCOHOLIC FATTY LIVER DISEASE AND INFLAMMATORY STEATOHEPATITIS WITH SLC25A1 INHIBITORS | SLC10A1, SLC27A1, SLC25A3 | SLC25A1 16/4885MEN1 4426/4885KMT2A 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.